

We Claim:

1. A composition for modulating cellular replication of porcine circovirus type B (PCV-B) comprising a pharmaceutically or veterinarily acceptable vehicle and an active agent comprising a PCV-B immunogen present in an amount effective to modulate cellular replication, wherein said immunogen is an inactivated PCV-B.
2. The composition of claim 1, wherein the immunogen is recombinantly produced.
3. A method for modulating cellular replication of porcine circovirus type B (PCV-B) in a pig comprising administering to the pig the composition of claim 1.
4. The method of claim 3, wherein the immunogen is recombinantly produced.
5. The method of claim 3, wherein the administering is prior to breeding.
6. The method of claim 3, wherein the administering is to a pregnant female pig.
7. A composition for inhibiting viral replication of porcine circovirus type B (PCV-B) comprising a pharmaceutically or veterinarily acceptable vehicle and an active agent comprising a PCV-B immunogen present in an amount effective to inhibit viral replication, wherein said immunogen is an inactivated PCV-B.
8. The composition of claim 7, wherein the immunogen is recombinantly produced.
9. A method for inhibiting viral replication of porcine circovirus type B (PCV-B) in a pig comprising administering to the pig the composition of claim 7.

10. The method of claim 9, wherein the immunogen is recombinantly produced.
11. The method of claim 9, wherein the administering is prior to breeding.
12. The method of claim 9, wherein the administering is to a pregnant female pig.